E

Eukarya Pharmasite | Monterrey, Mexico

Research site
(Unclaimed)
Location
Avenida de la Clinica 2520 Colonia Sertoma Consultorio 326, Monterrey, Nuevo León, Mexico

Site insights

Top conditions

Top treatments

Lebrikizumab
Orforglipron
LY3009104
Tirzepatide
Metformin
Retatrutide
LY3502970
LY3437943
Baricitinib
LY3298176

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 7 total trials
Locations recently updated

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib
Recently updated

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab
Locations recently updated

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo
Locations recently updated

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

Trial sponsors

Lilly logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems